Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Schlechter is a medical oncologist who specializes in gastrointestinal cancers including colorectal cancer, anal cancer, pancreatic cancer, and neuroendocrine cancers, among others. He is a former intern, resident, chief resident and fellow at Beth Israel Deaconess Medical Center as well as a member of the faculty at Harvard Medical School. In the past he was the Director of Inpatient Hematology and Oncology at Beth Israel Deaconess Medical Center as well as the Assistant Program Director of the Internal Medicine Residency Program. His work at Dana-Farber focuses on providing excellent patient care while trying to advance the treatment of gastrointestinal cancer patients.
My research interests focus on clinical innovations for patients with gastrointestinal malignancies. I am the Harvard-wide principal investigator for the PANOVA-3 clinical trial studying tumor treating fields in locally advanced pancreatic cancer; NUC-3373, a novel fluorouracil-like drug for colorectal cancer; and the ECOG EA2165 study of nivolumab after chemoradiotherapy for anal squamous cancer. I am on the Data Safety Monitoring Committees of PEN221 for advanced neuroendocrine tumors as well as AbGen107 for advanced gastrointestinal malignancies. I also have enrolled patients in multiple phase I, II, and III clinical trials for gastrointestinal malignancies. I was a lead enroller in the CATIQ phase II trial of isoquercetin to inhibit protein disulfide isomerase to prevent malignancy associated thrombosis in ambulatory cancer patients and have been an active participant in a study of fixed-dose versus weight- based enoxaparin as thromboprophylaxis for hospitalized cancer patients. In the past, I worked as a bench researcher in carcinogenesis in the laboratory of Carol Rosenberg at Boston University Medical Center and at the Wyss Institute for Biologically Inspired Engineering under the direction of Donald Ingber at HMS.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions
Dana-Farber Cancer Institute - Chestnut Hill300 Boylston StreetNewton, MA 02459Get Directions